8-K: Aligos Therapeutics Announces Positive Clinical Data and Third Quarter 2024 Financial Results

Aligos Therapeutics reported positive topline data for its MASH treatment and provided a financial update for the third quarter of 2024.

Summary

• Aligos Therapeutics announced positive topline data from its HERALD study for ALG-055009, a treatment for MASH, showing significant reductions in liver fat.
• The company is progressing ALG-000184 for CHB towards a Phase 2 study next year and expects to begin externally funded clinical studies for ALG-097558 in COVID subjects later this year.
• Aligos reported a net loss of $19.3 million for the third quarter of 2024, with research and development expenses at $16.8 million.
• As of September 30, 2024, the company had $74.9 million in cash, cash equivalents, and investments, which they believe is sufficient to fund operations through the end of 2025.

Sentiment

Score: 7

Explanation: The document presents positive clinical data and progress in multiple programs, but also highlights financial losses and the need for additional funding, resulting in a moderately positive sentiment.

Positives

• The HERALD study for ALG-055009 showed significant reductions in liver fat, indicating potential best-in-class status.
• ALG-055009 demonstrated a favorable tolerability profile.
• The company is progressing multiple drug candidates across different therapeutic areas.
• Aligos has secured external funding and collaborations for its clinical programs.
• The company believes its current cash balance is sufficient to fund operations through the end of 2025.

Negatives

• Aligos reported a net loss of $19.3 million for the third quarter of 2024.
• The company's cash balance decreased from $135.7 million at the end of 2023 to $74.9 million as of September 30, 2024.
• The company is evaluating options to fund continued development, including potential partnering, indicating a need for additional capital.

Risks

• The company is still in the clinical stage of development, and there are risks associated with clinical trials and regulatory approvals.
• Aligos relies on third parties for manufacturing and development efforts.
• The company faces competition in the biopharmaceutical industry.
• There are risks associated with the company's ability to protect its intellectual property.
• The company's future success depends on its ability to secure additional funding or partnerships.

Future Outlook

Aligos believes it is laying the groundwork for important future successes in 2025 and beyond, with plans to advance its clinical programs and explore funding options.

Management Comments

• Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics stated that the company reached a key milestone with the positive topline HERALD data in MASH subjects.
• Management believes ALG-055009 has best-in-class potential due to the significant reductions in liver fat.
• Management is evaluating a variety of options to fund continued development, including potential partnering.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on liver and viral diseases. The positive data for ALG-055009 in MASH positions Aligos as a potential competitor in this space. The collaborations and external funding also highlight the importance of partnerships in drug development.

Comparison to Industry Standards

• The 46.2% median reduction in liver fat with ALG-055009 is a strong result compared to other MASH treatments in development, such as those from Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809), which have shown similar but potentially less pronounced reductions in liver fat in their respective trials.
• The tolerability profile of ALG-055009, with no clinical hyper/hypothyroidism, is a positive differentiator compared to some other THR-beta agonists that have shown thyroid-related side effects.
• The collaboration with Xiamen Amoytop for ALG-000184 in China is similar to other biopharma companies seeking to expand their reach and accelerate development in key markets.
• The external funding for ALG-097558 from AGILE and NIAID is a positive sign of validation for the program and is similar to other companies leveraging government and non-profit funding for clinical trials.

Stakeholder Impact

• Shareholders may react positively to the clinical data but negatively to the financial losses and potential need for capital raising.
• Employees may be encouraged by the progress of the clinical programs.
• Patients may benefit from the development of new treatments for liver and viral diseases.
• Partners and collaborators may be interested in the progress of the company's programs.

Next Steps

• Complete Phase 2b enabling studies for ALG-055009.
• Evaluate options to fund continued development, including potential partnering.
• Progress ALG-000184 for CHB towards a Phase 2 study next year.
• Begin externally funded clinical studies for ALG-097558 later this year.
• Present additional interim data readouts at the AASLD The Liver Meeting (TLM) 2024.

Key Dates

Keywords

MASH, NASH, ALG-055009, ALG-000184, ALG-097558, Hepatitis B, COVID-19, Clinical Trials, Biopharmaceutical, Liver Disease, Viral Disease